PE20100153A1 - Nuevo procedimiento de obtencion de la forma cristalina v de la agomelatina - Google Patents

Nuevo procedimiento de obtencion de la forma cristalina v de la agomelatina

Info

Publication number
PE20100153A1
PE20100153A1 PE2009000980A PE2009000980A PE20100153A1 PE 20100153 A1 PE20100153 A1 PE 20100153A1 PE 2009000980 A PE2009000980 A PE 2009000980A PE 2009000980 A PE2009000980 A PE 2009000980A PE 20100153 A1 PE20100153 A1 PE 20100153A1
Authority
PE
Peru
Prior art keywords
agomelatin
obtaining
crystal
new procedure
crystalline
Prior art date
Application number
PE2009000980A
Other languages
English (en)
Inventor
Damien Martins
Julie Linol
Gerard Coquerel
Pascal Langlois
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40418877&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20100153(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of PE20100153A1 publication Critical patent/PE20100153A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/08—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Manufacture Of Metal Powder And Suspensions Thereof (AREA)

Abstract

REFERIDA A UNA FORMA CRISTALINA V DE AGOMELATINA DE FORMULA (I) QUE PRESENTA UN DIAGRAMA DE DIFRACCION X SOBRE POLVO CON VALORES DE ANGULOS DE BRAGG 2 THETA TALES COMO 9,84, 12,40, 13,31, 15,14, 15,98, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE OBTENCION DE LA AGOMELATINA CRISTALINA V MEDIANTE LA ATOMIZACION DE UNA DISOLUCION DE AGOMELATINA EN UNA CONCENTRACION DE 5 g/l, EN UN DISOLVENTE TAL COMO ETANOL Y ETER ISOPROPILICO, A UNA TEMPERATURA DE EBULLICION INFERIOR A 120 ºC
PE2009000980A 2008-08-05 2009-07-23 Nuevo procedimiento de obtencion de la forma cristalina v de la agomelatina PE20100153A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0804466A FR2934856B1 (fr) 2008-08-05 2008-08-05 Nouveau procede d'obtention de la forme cristalline v de l'agomelatine

Publications (1)

Publication Number Publication Date
PE20100153A1 true PE20100153A1 (es) 2010-03-06

Family

ID=40418877

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000980A PE20100153A1 (es) 2008-08-05 2009-07-23 Nuevo procedimiento de obtencion de la forma cristalina v de la agomelatina

Country Status (46)

Country Link
US (1) US8252957B2 (es)
EP (1) EP2151430B1 (es)
JP (1) JP5047240B2 (es)
KR (1) KR101118335B1 (es)
CN (1) CN101643432B (es)
AP (1) AP3196A (es)
AR (1) AR074889A1 (es)
AT (1) ATE518825T1 (es)
AU (1) AU2009203071B2 (es)
BR (1) BRPI0903058A2 (es)
CA (1) CA2674770C (es)
CL (1) CL2009001685A1 (es)
CO (1) CO6120151A1 (es)
CR (1) CR10952A (es)
CY (1) CY1111873T1 (es)
DK (1) DK2151430T3 (es)
EA (1) EA016896B1 (es)
EC (1) ECSP099554A (es)
ES (1) ES2371047T3 (es)
FR (1) FR2934856B1 (es)
GE (1) GEP20125408B (es)
GT (1) GT200900215A (es)
HK (1) HK1141005A1 (es)
HN (1) HN2009001437A (es)
HR (1) HRP20110712T1 (es)
IL (1) IL200126A (es)
JO (1) JO2812B1 (es)
MA (1) MA31223B1 (es)
ME (1) ME00929B (es)
MX (1) MX2009008046A (es)
MY (1) MY151042A (es)
NI (1) NI200900154A (es)
NZ (1) NZ578826A (es)
PE (1) PE20100153A1 (es)
PL (1) PL2151430T3 (es)
PT (1) PT2151430E (es)
RS (1) RS52002B (es)
SA (1) SA109300499B1 (es)
SG (1) SG158830A1 (es)
SI (1) SI2151430T1 (es)
SV (1) SV2009003345A (es)
TW (1) TW201008901A (es)
UA (1) UA102816C2 (es)
UY (1) UY32014A (es)
WO (1) WO2010015747A1 (es)
ZA (1) ZA200905334B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101781226B (zh) 2009-12-23 2012-03-28 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物
WO2012093402A1 (en) * 2011-01-04 2012-07-12 Symed Labs Limited Processes for the preparation of n-[2-(7-methoxy-1-naphthyl)ethyl]acetamide
WO2012130837A1 (en) 2011-03-28 2012-10-04 Ratiopharm Gmbh Solid agomelatine in non-crystalline form
EP2872129B1 (en) 2012-07-16 2017-03-08 ratiopharm GmbH Complex of agomelatine and cyclodextrin
WO2015124496A1 (en) 2014-02-19 2015-08-27 Synthon B.V. Pharmaceutical composition comprising amorphous agomelatine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1703641A1 (ru) * 1988-02-23 1992-01-07 Ростовский государственный университет Способ получени 3,5-ди-трет.бутил-4-оксиацетанилида
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
YU48420B (sh) * 1991-03-25 1998-07-10 Hoechst Aktiengesellschaft Postupak za dobijanje biološki razgradljivih mikročestica sa dugotrajnim delovanjem
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
FR2889522B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889521B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889523B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
US20080280991A1 (en) * 2007-05-08 2008-11-13 Auspex Pharmaceuticals, Inc. Substituted naphthalenes
FR2923482B1 (fr) * 2007-11-09 2010-01-29 Servier Lab Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
KR20100017070A (ko) 2010-02-16
CY1111873T1 (el) 2015-11-04
IL200126A0 (en) 2010-05-31
JO2812B1 (en) 2014-09-15
SV2009003345A (es) 2010-02-01
FR2934856A1 (fr) 2010-02-12
CN101643432B (zh) 2012-12-12
EP2151430B1 (fr) 2011-08-03
PT2151430E (pt) 2011-08-25
AU2009203071A1 (en) 2010-02-25
BRPI0903058A2 (pt) 2010-05-25
MY151042A (en) 2014-03-31
RS52002B (en) 2012-04-30
IL200126A (en) 2013-04-30
SA109300499B1 (ar) 2013-10-06
HK1141005A1 (en) 2010-10-29
NZ578826A (en) 2010-11-26
ECSP099554A (es) 2010-03-31
CA2674770A1 (fr) 2010-02-05
AP2009004936A0 (en) 2009-08-31
UY32014A (es) 2010-01-29
EP2151430A1 (fr) 2010-02-10
EA200900944A1 (ru) 2010-04-30
GT200900215A (es) 2011-07-19
DK2151430T3 (da) 2011-11-21
NI200900154A (es) 2010-03-25
CL2009001685A1 (es) 2010-07-19
KR101118335B1 (ko) 2012-03-09
SI2151430T1 (sl) 2011-10-28
JP2010037345A (ja) 2010-02-18
HRP20110712T1 (hr) 2011-11-30
CA2674770C (fr) 2012-04-17
CN101643432A (zh) 2010-02-10
AU2009203071B2 (en) 2013-10-31
US20100036165A1 (en) 2010-02-11
GEP20125408B (en) 2012-02-27
EA016896B1 (ru) 2012-08-30
WO2010015747A1 (fr) 2010-02-11
CO6120151A1 (es) 2010-01-29
AP3196A (en) 2015-03-31
SG158830A1 (en) 2010-02-26
TW201008901A (en) 2010-03-01
UA102816C2 (ru) 2013-08-27
AR074889A1 (es) 2011-02-23
JP5047240B2 (ja) 2012-10-10
FR2934856B1 (fr) 2010-08-13
HN2009001437A (es) 2011-09-22
CR10952A (es) 2009-10-15
ATE518825T1 (de) 2011-08-15
ES2371047T3 (es) 2011-12-26
PL2151430T3 (pl) 2011-12-30
MA31223B1 (fr) 2010-03-01
US8252957B2 (en) 2012-08-28
MX2009008046A (es) 2010-03-23
ME00929B (me) 2012-06-20
ZA200905334B (en) 2010-05-26

Similar Documents

Publication Publication Date Title
PH12015500119A1 (en) Composition for controlling plant disease and application therefor
NZ710855A (en) Molecules having certain pesticidal utilities, and intermediates, compositions, and processes related thereto
EA201071320A1 (ru) Активаторы глюкокиназы
WO2014147525A3 (en) Perylenemonoimide and naphthalenemonoimide derivatives and their use in dye-sensitized solar cells
WO2014199352A3 (en) Lipid-based platinum-n-heterocyclic carbene compounds and nanoparticles
DOP2010000357A (es) Derivados de indazoles sustituidos con fenilo o piridinilo
EA033811B1 (ru) Стабильные бесконсервантные мидриатические и противовоспалительные растворы для инъекций
PE20100153A1 (es) Nuevo procedimiento de obtencion de la forma cristalina v de la agomelatina
MX2011007998A (es) Nuevos herbicidas.
MY161132A (en) Novel herbicides
IN2015DN03898A (es)
MX2011007932A (es) Herbicidas nuevos.
WO2014033582A3 (en) Diketopyrrolopyrole (dpp)-based sensitizers for electrochemical or optoelectronic devices
BR112015026441A2 (pt) derivados de fulereno aperfeiçoados e materiais, métodos e dispositivos relacionados
MX347373B (es) Soluciones anti-inflamatorias estables para inyección.
BR112014002940A2 (pt) uso e composição agroquímica de dibutilamidas de ácido carboxílico
MX2010006787A (es) Análogos halogenados de agentes anti-fibroticos.
WO2014197197A8 (en) High temperature geomembrane liners and master batch compositions
CL2016001165A1 (es) Proceso preparativo. (divisional sol. n° 3003-2014)
EA201391198A1 (ru) Несмываемая, нетвердая, кондиционирующая кожу композиция, которая имеет диспергирующую масляную фазу и содержит 12-гидроксистеариновую кислоту
WO2011012247A8 (de) 2-(3-alkylthiobenzoyl)cyclohexandione und ihre verwendung als herbizide
WO2011100189A3 (en) Process for preventing or mitigating biofouling
CL2012003497A1 (es) Procedimiento para preparar el compuesto diácido 3,6,9-triaza-3,6,9-tris(carboximetil)-4-(4-etoxibencil)-undecanoico cristalino; su uso para preparar una formulación galénica del complejo de gadolinio de diacido 3,6,9-triaza-3,6,9-tris(carboximetil)-4-(4-etoxibencil)-undecanoico; y el compuesto con una pureza superior al 99%.
Ramachandra Raja et al. Growth and spectral characterization of ethylene diamine tetra acetic acid (EDTA) doped zinc sulphate hepta hydrate-A semi organic NLO material
WO2013105873A8 (en) Semiconducting thin [60]fullerene films and their use

Legal Events

Date Code Title Description
FC Refusal